Pfizer Inc. (PFE) — Quantitative Forecast & Factor Scores

PFE currently carries a valuation grade of Strong Buy. The trailing P/E of 20.1 is roughly in line with the Healthcare sector median of 22.0x. Our discounted cash flow model suggests an intrinsic range of $34–$58, implying a +69% margin of safety at the current price of $27.32.

With a beta of 0.41, PFE exhibits a low-volatility risk profile relative to the broad market. Net margins of 12.4% fall below the Healthcare average of 18%, suggesting potential margin pressure. Return on equity stands at 8.9%. The balance sheet is conservatively leveraged at 78% debt-to-equity.

With a 58% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter delivered a +10.0% earnings surprise. Analyst estimate revisions are trending accelerating.

Insider transactions show net buying of $70,949,446 over the trailing period, a signal often associated with management confidence. Short interest is low at 2.5% of float, suggesting limited bearish conviction.

At 0.69, the put/call ratio skews bullish, with call buyers dominating recent flow. Implied volatility of 37.3% exceeds realized volatility of 21.9% by 15 points, suggesting options are pricing in elevated risk.

Among closely correlated names, PFE shows the strongest co-movement with MRK (0.70), BMY (0.67), AZN (0.57). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.